Oculis Holding AG (OCS) CHF0.01
Sell:$13.00Buy:$20.17
$0.86
(5.06%)
- This stock can be held in a
Stocks and Shares ISA$0.86
(5.06%)$0.86
(5.06%)Company Information
About this company
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Key people
Key facts
- EPICOCS
- LocationSwitzerland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINCH1242303498
- Market cap$797.29m
- Employees49
- Shares in issue47.94m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.